Teva Pharma (TEVA) Reports In-Line Q3 EPS, Beats on Revenue; Offers FY23 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Teva Reports Third Quarter 2023 Financial Results and Increases Revenue Guidance
November 8, 2023 7:00 AM EST2023 revenues outlook revised to $15.1 - $15.5 billion from $15.0 - $15.4 billion
Global revenues of $3.9 billion, reflect an increase of 7% from the third quarter of 2022 Increased revenues reflect sustained growth of AUSTEDO®, AJOVY® and global generics business: Growth of AUSTEDO in North America Growth of AJOVY globally Stable and sustainable generics business in the U.S.; continued growth in Europe and International Markets GAAP diluted EPS of $0.07 Non-GAAP diluted EPS of $0.60 Cash flow generated from operating activities of $5 million Free cash flow of $229... More